Transcervical radiofrequency ablation of fibroids that are 5 cm or larger in women with abnormal uterine bleeding - 30/12/21
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Introduction: Fibroids are the most common benign uterine tumors. Transcervical radiofrequency ablation with the Sonata® System offers a minimally invasive, incisionfree, organ-preserving therapy, with intraoperative visualization of fibroids using intrauterine ultrasound guidance. To demonstrate the effectiveness of transcervical radiofrequency ablation of fibroids that are 5 cm or larger using the Sonata® System, this retrospective analysis was collected.
Method: 151 patients have been treated with this method in our department up to the time of this analysis. Only patients with at least one fibroid of ≥5cm and with bleeding symptoms, who were treated with the Sonata® System were included in this retrospective study. A total of 50 patients were included in the study and 57 fibroids were treated.
Results: A total of 57 fibroids were detected and treated, however FIGO 1 and 2 fibroids (in total three fibroids were excluded). The smallest fibroid was 4cm and the largest fibroid was 12cm. A single ablation was performed in 18 cases, two ablation steps in 16 cases, three ablation steps in 13 cases, and more than three ablation steps in three cases. Depending on ablation steps, the shortest ablation time was 3 minutes 15 seconds and the longest ablation time was 25 minutes 6 seconds, with an average time of 9 minutes 12 seconds. 86% of patients reported an improvement of symptoms
Conclusion: Thus, the Sonata® System is a simple, minimally invasive, rapid and successful method that shows significant improvement of symptoms even in large myomas from ≥5 cm.
Le texte complet de cet article est disponible en PDF.Keywords : Sonata® System, Myoma, Transcervical Radiofrequency Ablation, Fibroid, Uterine Bleeding
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?